Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: evidence from the Framingham Heart Study

Table 2 Single-SNP association test results for T2D status confirmed by regression analysis

SNP	Gene	Chr	Position	RAF	OR (95% CI)	R²	P ^a
rs2793823	ADAM30	1p	120239241	G, 0.89	2.0 (0.3-13.0) 2.2 (0.4-14.1)	0.0007	0.4762 0.3905
rs17030946	THADA	2p	43587013	T, 0.10	1.2 (0.3-5.2) 0.8 (0.5-1.2)	0.0044	0.793 0.2617
rs4607103	ADAMTS9	3p	64686944	C, 0.74	1.1 (0.6-2.1) 1.1 (0.6-2.1)	0.0002	0.6784 0.3905
rs1801282	PPARG	3p	12368125	G, 0.11	1.2 (0.1-28.7) 0.9 (0.6-1.3)	0.0004	0.8895 0.625
rs4402960	IGF2BP2	3q	186994381	G, 0.67	1.2 (0.8-2.0) 1.2 (0.7-1.9)	0.0014	0.3728 0.5386
rs5018648	WFS1	4p	6343719	G, 0.61	1.1 (0.7-1.6) 1.0 (0.6-1.4)	0.0017	0.8127 0.8432
rs10946398	CDKAL1	6p	20769013	C, 0.33	1.2 (0.7-2.1) 1.3 (0.9-2.1)	0.0014	0.4013 0.1858
rs864745	JAZF1	7p	28147081	A, 0.52	1.5 (1.0-2.3) 1.1 (0.8-1.6)	0.0043	0.0427 ^b 0.6146
rs10282940	SLC30A8	8q	118257007	G, 0.89	1.3 (0.4-4.5) 1.3 (0.4-4.3)	0.0006	0.6785 0.7141
rs10811661	CDKN2A/2B	9p	22124094	T, 0.82	2.1 (1.0-4.4) 1.3 (0.6-2.9)	0.0061	0.0424 0.4428
rs564398	CDKN2A/2B	9p	22019547	G, 0.39	1.1 (0.7-1.9) 1.0 (0.8-1.4)	0.0007	0.5892 0.7728
rs4506565	TCF7L2	10q	114748339	T, 0.36	2.0 (1.2-3.1) 1.4 (0.9-2.0)	0.0045	0.0041 0.0932
rs5215	KCNJ11	11p	17365206	C, 0.36	1.0 (0.6-1.7) 0.7 (0.5-1.0)	0.0039	0.9201 0.0619
rs7961581	TSPAN8-LGR5	12q	69949369	T, 0.70	1.1 (0.7-1.8) 1.3 (0.8-2.2)	0.0024	0.6417 0.2377
rs8050136	FTO	16q	52373776	A, 0.41	1.1 (0.7-1.7) 0.9 (0.7-1.2)	0.001	0.6854 0.6667

^aLogistic-GEE regression p for genotypes homozygous (line 1) and heterozygous (line 2) for a risk allele with genotype homozygous for a non-risk allele as reference.
^bBold font indicates significant p-values.

ISSN: 1753-6561